TEVERELIX TRIFLUOROACETATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C74H100ClN15O14.2C2HF3O2
Molecular Weight	1687.178
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC(C)C[C@H](NC(=O)[C@@H](CCCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC2=CC=CN=C2)NC(=O)[C@@H](CC3=CC=C(Cl)C=C3)NC(=O)[C@@H](CC4=CC=C5C=CC=CC5=C4)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N6CCC[C@H]6C(=O)N[C@H](C)C(N)=O

InChI

InChIKey=XCOCXBFSPCRONC-SAECRDNQSA-N

InChI=1S/C74H100ClN15O14.2C2HF3O2/c1-43(2)35-57(66(96)84-56(19-10-11-32-79-44(3)4)73(103)90-34-14-20-63(90)72(102)81-45(5)64(76)94)85-65(95)55(18-9-12-33-80-74(77)104)83-68(98)59(38-48-24-29-54(93)30-25-48)88-71(101)62(42-91)89-70(100)61(40-50-15-13-31-78-41-50)87-69(99)60(37-47-22-27-53(75)28-23-47)86-67(97)58(82-46(6)92)39-49-21-26-51-16-7-8-17-52(51)36-49;2*3-2(4,5)1(6)7/h7-8,13,15-17,21-31,36,41,43-45,55-63,79,91,93H,9-12,14,18-20,32-35,37-40,42H2,1-6H3,(H2,76,94)(H,81,102)(H,82,92)(H,83,98)(H,84,96)(H,85,95)(H,86,97)(H,87,99)(H,88,101)(H,89,100)(H3,77,80,104);2*(H,6,7)/t45-,55-,56+,57+,58-,59+,60-,61-,62+,63+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C74H100ClN15O14
Molecular Weight	1459.131
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	3
Optical Activity	UNSPECIFIED

Molecular Formula	C2HF3O2
Molecular Weight	114.0233
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10872648 | https://www.ncbi.nlm.nih.gov/pubmed/20514551 | https://www.ncbi.nlm.nih.gov/pubmed/12878396

Teverelix is a polypeptide gonadotropin-releasing hormone (GnRH) antagonist which was being developed by Ardana Bioscience for the treatment of prostate cancer and benign prostatic hyperplasia. Compared with other GnRH antagonists, Teverelix is characterized by relatively good water solubility, little in vitro aggregation, and low histamine-releasing potency, with a dose that produces the halfmaximal response. In preclinical studies, Teverelix has been shown to exert antiovulatory activity. In phase I clinical trials Teverelix shows pronounced luteinizing hormone and testosterone suppressive effects after single subcutaneous doses in healthy men.

Approval Year

PubMed

Title	Date	PubMed
Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay.	1997 Aug 15	9300077
Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.	2000 Jun	10872648

Patents

Sample Use Guides

In Vivo Use Guide

0.5, 1, 2, 3, or 5 mg

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Sat Dec 16 15:16:41 GMT 2023` Edited by `admin` on `Sat Dec 16 15:16:41 GMT 2023`
Record UNII	J5OUL9SHW5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TEVERELIX TRIFLUOROACETATE

Common Name

English

D-ALANINAMIDE, N-ACETYL-3-(2-NAPHTHALENYL)-D-ALANYL-4-CHLORO-D-PHENYLALANYL-3-(3-PYRIDINYL)-D-ALANYL-L-SERYL-L-TYROSYL-N6-(AMINOCARBONYL)-D-LYSYL-L-LEUCYL-N6-(1-METHYLETHYL)-L-LYSYL-L-PROLYL-, BIS(TRIFLUOROACETATE) (SALT)

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C179714